Jpmorgan Chase & CO Xenon Pharmaceuticals Inc. Transaction History

Jpmorgan Chase & CO

  • $1.27 Trillion
  • Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,357,602 shares of XENE stock, worth $54.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,357,602
Previous 1,356,895 0.05%
Holding current value
$54.3 Million
Previous $53.2 Million 14.37%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
BUY
$33.55 - $40.74 $23,719 - $28,803
707 Added 0.05%
1,357,602 $45.5 Million
Q4 2024

Feb 12, 2025
BUY
$38.14 - $45.74 $14.5 Million - $17.4 Million
380,112 Added 38.91%
1,356,895 $53.2 Million
Q3 2024

Dec 26, 2024
BUY
$36.12 - $43.96 $32.7 Million - $39.8 Million
905,129 Added 1263.19%
976,783 $38.4 Million
Q3 2024

Nov 08, 2024
BUY
$36.12 - $43.96 $32.7 Million - $39.8 Million
905,129 Added 1263.19%
976,783 $38.4 Million
Q2 2024

Dec 26, 2024
SELL
$36.25 - $43.75 $32.8 Million - $39.6 Million
-905,129 Reduced 92.66%
71,654 $2.79 Million
Q2 2024

Aug 12, 2024
BUY
$36.25 - $43.75 $1.27 Million - $1.53 Million
35,033 Added 95.66%
71,654 $2.79 Million
Q1 2024

Dec 26, 2024
SELL
$42.66 - $50.04 $40.1 Million - $47 Million
-940,162 Reduced 96.25%
36,621 $1.58 Million
Q1 2024

May 10, 2024
SELL
$42.66 - $50.04 $689,684 - $808,996
-16,167 Reduced 30.63%
36,621 $1.58 Million
Q4 2023

Dec 26, 2024
SELL
$28.7 - $46.46 $26.5 Million - $42.9 Million
-923,995 Reduced 94.6%
52,788 $2.43 Million
Q4 2023

Feb 12, 2024
BUY
$28.7 - $46.46 $71,491 - $115,731
2,491 Added 4.95%
52,788 $2.43 Million
Q3 2023

Nov 14, 2023
SELL
$34.16 - $39.73 $987,907 - $1.15 Million
-28,920 Reduced 36.51%
50,297 $1.72 Million
Q2 2023

Aug 11, 2023
BUY
$34.84 - $43.54 $1.62 Million - $2.02 Million
46,430 Added 141.61%
79,217 $3.05 Million
Q1 2023

May 11, 2023
BUY
$33.46 - $40.35 $1.03 Million - $1.24 Million
30,700 Added 1471.01%
32,787 $1.17 Million
Q4 2022

Feb 13, 2023
SELL
$33.06 - $39.43 $72,203 - $86,115
-2,184 Reduced 51.14%
2,087 $82,000
Q3 2022

Nov 14, 2022
BUY
$30.79 - $39.82 $56,191 - $72,671
1,825 Added 74.61%
4,271 $155,000
Q2 2022

Aug 11, 2022
SELL
$25.44 - $35.16 $99,852 - $138,003
-3,925 Reduced 61.61%
2,446 $74,000
Q1 2022

May 11, 2022
BUY
$25.09 - $33.13 $40,043 - $52,875
1,596 Added 33.42%
6,371 $194,000
Q4 2021

Feb 10, 2022
BUY
$15.6 - $35.4 $27,471 - $62,339
1,761 Added 58.43%
4,775 $149,000
Q3 2021

Nov 12, 2021
BUY
$14.86 - $19.45 $44,788 - $58,622
3,014 New
3,014 $46,000

Others Institutions Holding XENE

# of Institutions
221
Shares Held
72.7M
Call Options Held
336K
Put Options Held
309K
View Full List

About Xenon Pharmaceuticals Inc.

XENE Quotes by TradingView
  • Ticker XENE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,263,500
  • Market Cap $2.49B
  • Description
  • Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...
More about XENE
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email